Impact of sirtuin‑1 expression on progression‑free survival in non‑endometrioid endometrial cancer: A retrospective cohort study

Yalcin,Necim; Yildirim,Hulya Tosun; Alci,Aysun; Gokkaya,Mustafa; Goksu,Mehmet; Ureyen,Isin; Toptas,Tayfun

doi:10.3892/ol.2025.14985

Impact of sirtuin‑1 expression on progression‑free survival in non‑endometrioid endometrial cancer: A retrospective cohort study

Authors:
- Necim Yalcin
- Hulya Tosun Yildirim
- Aysun Alci
- Mustafa Gokkaya
- Mehmet Goksu
- Isin Ureyen
- Tayfun Toptas
View Affiliations

Affiliations: Department of Gynecological Oncology, Saglik Bilimleri University Antalya Training and Research Hospital, 07100 Antalya, Turkey, Department of Pathology, Saglik Bilimleri University Antalya Training and Research Hospital, 07100 Antalya, Turkey
Published online on: March 20, 2025 https://doi.org/10.3892/ol.2025.14985
Article Number: 239
Copyright: © Yalcin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sirtuin‑1 (SIRT1) expression levels are upregulated in various types of cancer and are associated with adverse outcomes. However, there is limited research on SIRT1 expression in types of gynecological cancer. The present study primarily sought to investigate the expression characteristics of SIRT1 in non‑endometrioid endometrial cancer (EC) using immunohistochemistry. The secondary endpoint was to evaluate the impact of SIRT1 expression levels on progression‑free survival (PFS). The present study was a single‑center, retrospective cohort study that included patients who underwent hysterectomy between June 2017 and December 2021 and had a postoperative histopathological diagnosis of non‑endometrioid EC. The tissue slides were stained with a monoclonal antibody targeting the SIRT1 protein. The nuclear staining reaction of SIRT1 was considered to be positive in the presence of any percentage of nuclear staining. The cytoplasmic staining reaction of SIRT1 was assessed using the immune reactivity scoring (IRS) system, which was determined by multiplying the scores for the staining percentage and staining intensity. IRS values of 0 to 2 were considered as negative expression; 3 to 4 as low expression; 6 to 8 as moderate expression; and 9 to 12 as high expression. Cox proportional hazards regression models were used to identify factors influencing PFS. Data from a total of 43 patients who met the eligibility criteria were presented. Cytoplasmic staining with SIRT1 was detected in all samples (100%), whereas no nuclear staining was evident in any of the tissue samples. According to the IRS results, 20.9% of samples exhibited negative cytoplasmic expression, 14.0% exhibited low expression, 37.2% exhibited moderate expression and 27.9% exhibited high expression. The estimated 3‑year PFS rate was 43.6%. Cox regression models demonstrated no independent factor influencing PFS. In conclusion, SIRT1 expression was found to be cytoplasmic in non‑endometrioid EC. According to the IRS, ~80% of cases exhibited varying degrees of SIRT1 expression. However, SIRT1 expression levels had no significant impact on PFS.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Åkesson Å, Adok C and Dahm-Kähler P: Recurrence and survival in endometrioid endometrial cancer-a population-based cohort study. Gynecol Oncol. 168:127–134. 2023. View Article : Google Scholar : PubMed/NCBI
3	Åkesson Å, Adok C and Dahm-Kähler P: Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy-A population-based cohort study. Eur J Cancer. 169:54–63. 2022. View Article : Google Scholar : PubMed/NCBI
4	Lee SJ, Kang HJ, Kwak YK, Kim M and Kim J: Non-endometrioid endometrial cancer: Analysis of recurrence pattern and identification of prognostic and treatment factors affecting recurrence and survival. Strahlenther Onkol. 199:828–837. 2023. View Article : Google Scholar : PubMed/NCBI
5	Feng J, Zhang Y, Huang C, Li L, Liu J, Wang J, Guo H, Yao S, Cui Z, Chen G, et al: Prognostic evaluation of lymph-vascular space invasion in patients with endometrioid and non-endometrioid endometrial cancer: A multicenter study. Eur J Surg Oncol. 50:1082612024. View Article : Google Scholar : PubMed/NCBI
6	Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, et al: Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 22:4215–4224. 2016. View Article : Google Scholar : PubMed/NCBI
7	Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, et al: Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J Pathol Clin Res. 3:279–293. 2017. View Article : Google Scholar : PubMed/NCBI
8	León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock PM, Bessette P, et al: Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 38:3388–3397. 2020. View Article : Google Scholar : PubMed/NCBI
9	Uijterwaal MH, van Dijk D, Lok CAR, De Kroon CD, Kasius JC, Zweemer R, Gerestein CG, Horeweg N, Bosse T, van der Marel J, et al: Prognostic value of molecular classification in stage IV endometrial cancer. Int J Gynecol Cancer. 34:847–854. 2024. View Article : Google Scholar : PubMed/NCBI
10	Vizza E, Bruno V, Cutillo G, Mancini E, Sperduti I, Patrizi L, Certelli C, Zampa A, Giannini A and Corrado G: Prognostic role of the removed vaginal cuff and its correlation with L1CAM in low-risk endometrial adenocarcinoma. Cancers (Basel). 14:342021. View Article : Google Scholar : PubMed/NCBI
11	Giannini A, D'Oria O, Corrado G, Bruno V, Sperduti I, Bogani G, Laganà AS, Chiantera V, Caserta D and Vizza E: The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: A systematic review and meta-analysis. Arch Gynecol Obstet. 309:789–799. 2024. View Article : Google Scholar : PubMed/NCBI
12	Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, Liu YS, Zheng G, Zhao JQ, Wei YF, et al: The sirtuin family in health and disease. Signal Transduct Target Ther. 7:4022022. View Article : Google Scholar : PubMed/NCBI
13	Yuan H and Marmorstein R: Structural basis for sirtuin activity and inhibition. J Biol Chem. 287:42428–42435. 2012. View Article : Google Scholar : PubMed/NCBI
14	Michishita E, Park JY, Burneskis JM, Barrett JC and Horikawa I: Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
15	Costa-Machado LF and Fernandez-Marcos PJ: The sirtuin family in cancer. Cell Cycle. 18:2164–2196. 2019. View Article : Google Scholar : PubMed/NCBI
16	Zhao E, Hou J, Ke X, Abbas MN, Kausar S, Zhang L and Cui H: The roles of sirtuin family proteins in cancer progression. Cancers (Basel). 11:19492019. View Article : Google Scholar : PubMed/NCBI
17	Saffar H, Nili F, Sarmadi S, Barazandeh E and Saffar H: Evaluation of sirtuin1 overexpression by immunohistochemistry in cervical intraepithelial lesions and invasive squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 31:128–131. 2023. View Article : Google Scholar : PubMed/NCBI
18	Zeng Z, Huang Y, Li Y, Huang S, Wang J, Tang Y and Jiang Y: Gene expression and prognosis of sirtuin family members in ovarian cancer. Medicine (Baltimore). 99:e206852020. View Article : Google Scholar : PubMed/NCBI
19	Han O, Alci A, Yildirim HT, Gokkaya M, Yalcin N, Kandemir S, Goksu M, Ureyen I and Toptas T: βcatenin expression in endometrioid type endometrial cancer: Expression patterns and impact on disease outcomes. Oncol Lett. 28:5802024. View Article : Google Scholar : PubMed/NCBI
20	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ERICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.PubMed/NCBI
21	Lin L, Zheng X, Qiu C, Dongol S, Lv Q, Jiang J, Kong B and Wang C: SIRT1 promotes endometrial tumor growth by targeting SREBP1 and lipogenesis. Oncol Rep. 32:2831–2835. 2014. View Article : Google Scholar : PubMed/NCBI
22	Huang S, Li Y, Sheng G, Meng Q, Hu Q, Gao X, Shang Z and Lv Q: Sirtuin 1 promotes autophagy and proliferation of endometrial cancer cells by reducing acetylation level of LC3. Cell Biol Int. 45:1050–1059. 2021. View Article : Google Scholar : PubMed/NCBI
23	Bartosch C, Monteiro-Reis S, Almeida-Rios D, Vieira R, Castro A, Moutinho M, Rodrigues M, Graça I, Lopes JM and Jerónimo C: Assessing sirtuin expression in endometrial carcinoma and non-neoplastic endometrium. Oncotarget. 7:1144–1154. 2016. View Article : Google Scholar : PubMed/NCBI
24	Asaka R, Miyamoto T, Yamada Y, Ando H, Mvunta DH, Kobara H and Shiozawa T: Sirtuin 1 promotes the growth and cisplatin resistance of endometrial carcinoma cells: A novel therapeutic target. Lab Invest. 95:1363–1373. 2015. View Article : Google Scholar : PubMed/NCBI
25	Al-Maghrabi J and Al-Maghrabi H: SIRT1 is overexpressed in endometrial adenocarcinoma: A tissue microarray analysis. Eur J Gynaecol Oncol. 41:699–704. 2020. View Article : Google Scholar
26	Beyer S, Chen F, Meister S, Czogalla B, Kolben TM, Hester A, Burges A, Trillsch F, Schmöckel E, Mayr D, et al: Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. Histochem Cell Biol. 154:189–195. 2020. View Article : Google Scholar : PubMed/NCBI